Now its time to get CEO Squarer on CNBC and in the IBD, Its time to brag !!
Great results hopefully FDA will push it through quickly, maybe fast track also orphan drug status, but way too small a market to garner any interest
I'd restate that a bit--it's too small a market to generate any meaningful income, but as a proof of concept it will generate a fair bit of interest.
Possible breakthrough designation